Tag: Protective

Categories
Health

The Pfizer-BioNTech Vaccine Is Stated to Be Powerfully Protecting in Adolescents

The Pfizer-BioNTech Vaccine Is Said to Be Powerfully Protective in Adolescents

The Pfizer BioNTech coronavirus vaccine is extremely effective in adolescents ages 12 to 15, perhaps even more effective than it is in adults, the companies reported on Wednesday. No symptomatic infections were found in children who received the vaccine in a recent clinical study. The children showed strong antibody reactions and did not show any serious side effects.

The results, if persistent, could accelerate the return to normal for millions of American families. Depending on government approval, vaccinations for middle school, high school and elementary school children might start not long before the start of the next school year.

The companies announced the results in a press release that did not include detailed data from the study that had not yet been peer-reviewed or published in a scientific journal. Still, the news was praised and excited by experts.

“Oh my god, I’m so happy to see this – it’s amazing,” said Akiko Iwasaki, an immunologist at Yale University. If the vaccine performance was A-plus in adults, the results in children were A-plus-plus.

The good news comes even if the country sees a renewed surge in infections and health officials again urge Americans to follow precautions and get vaccinated. On Monday, Dr. Rochelle Walensky, director of the Centers for Disease Control and Prevention, said rising cases left her feeling of “impending doom” while President Biden urged state and local officials to reinstate mask mandates.

Vaccination efforts are accelerating across the country. By Tuesday, 29 percent of Americans had received at least one dose of a coronavirus vaccine, and 16 percent had been fully vaccinated, according to the CDC

But the country cannot hope to achieve herd immunity – the point where immunity becomes so widespread that the coronavirus is slowing its passage through the population – without vaccinating the youngest Americans as well, some experts say. Children under the age of 18 make up approximately 23 percent of the population in the United States.

“The sooner we can get vaccines against as many people as possible, regardless of their age, the sooner we will feel like we are ending this pandemic for good,” said Angela Rasmussen, a virologist at Georgetown University in Washington.

Data from Israel suggest that vaccination in adults alone can significantly reduce the number of cases. “However, in order to reach the herd immunity threshold in the long term, we need to vaccinate children,” she said.

The study included 2,260 adolescents aged 12 to 15 years. The children received two doses of the vaccine three weeks apart – the same amounts and the same schedule as for adults – or a placebo with salt water.

The researchers registered 18 cases of symptomatic coronavirus infection in the placebo group and none among the children who received the vaccine. However, the low number of infections makes it difficult to accurately determine the effectiveness of the vaccine in the general population, said Dr. Rasmussen.

“But obviously it looks good for the vaccine if there are no Covid cases among the vaccinated people,” she added.

The adolescents who received the vaccine produced, on average, many more antibodies than those aged 16-25 in a previous study. The children experienced the same minor side effects as older participants, although the companies refused to be more specific.

Updated

March 31, 2021, 9:45 a.m. ET

Dr. Iwasaki said she expected antibody levels in teenagers to be comparable to those in young adults. “But they get even better readings from the vaccines,” she said. “That is really unbelievable.”

She and other experts warned that the vaccine may be less effective in children and adults against some of the variants that have come into circulation in the United States.

Pfizer and BioNTech started a clinical trial of the vaccine in children under the age of 12 just last week, and started vaccinating children ages 5 to 11. Scientists at the company plan to test the vaccine in even younger children ages 2 to 5 next week, followed by trials in children ages 6 months to 2 years.

Results from this three-phase study are expected in the second half of the year, and the companies hope to make the vaccine available to children under the age of 12 early next year.

“We share the urgency to expand the use of our vaccine to wider populations and are encouraged by data from clinical trials in adolescents 12-15 years of age,” said Albert Bourla, Pfizer chairman and CEO, in a statement.

Moderna has also tested its vaccine in children. Results of a study in adolescents aged 12 to 17 years are expected in the next few weeks and in children aged 6 months to 12 years in the second half of this year.

AstraZeneca started testing its vaccine in children 6 months and older last month, and Johnson & Johnson has announced that it will wait for the results of studies in older children before testing the vaccine in children under the age of 12.

Some parents have stated that they are reluctant to immunize their children because the risk of the virus is low. Children account for less than 1 percent of deaths from Covid-19, but about 2 percent of children with the disease require hospital care.

The new results may not affect all of these parents, but they can reassure parents who have been wary of vaccines, said Jennifer Nuzzo, an epidemiologist at the Johns Hopkins Center for Health Security.

“While I don’t think we have to wait for the children to be vaccinated to fully reopen schools, the ability to vaccinate children can help some families feel more secure when they return to school,” said they.

Pfizer and BioNTech plan to apply to the Food and Drug Administration for an emergency approval change for their vaccine in hopes of starting vaccinating older children before the start of the next school year. The companies also plan to submit their data for review and publication in a scientific journal.

You will monitor participants for two years after the second dose to assess the long-term safety and effectiveness of the vaccine. Vaccine side effects usually appear within the first six weeks, said Dr. Kristin Oliver, pediatrician and vaccine expert at Mount Sinai Hospital in New York. “Even so, it is good to know that security surveillance is continuing,” she said.

The CDC recommends that people do not receive any other vaccines for two weeks before and after receiving the two doses of the coronavirus vaccine.

But kids are getting more vaccines than ever before in the few weeks leading up to the school year, according to Dr. Oliver. Therefore, pediatricians and parents should try to get these other vaccinations earlier than usual.

The coronavirus vaccines should ideally be given by pediatricians with extensive experience immunizing children, added Dr. Oliver added. “Now is the time to plan how this rollout will take place in this age group,” she said.

Categories
Health

AstraZeneca Shot Discovered to Be Protecting Towards Coronavirus Variant First Seen in U.Okay.

AstraZeneca Shot Found to Be Protective Against Coronavirus Variant First Seen in U.K.

The Covid-19 vaccine developed by AstraZeneca and Oxford University protected people from a new, more contagious variant of coronavirus on a similar level as protection against other lineages of the virus, Oxford researchers said in an article published on Friday.

The paper, which has not yet been peer-reviewed, said the vaccine had an effectiveness of 74.6 percent over the new variant, first detected in the UK and known as B.1.1.7. This was similar, if slightly less than, its effectiveness against other lines of the virus.

The encouraging, if preliminary, results suggest that all five leading vaccines may offer at least some protection against new variants of the virus that is found around the world. However, the increasing evidence suggests that mutant viruses can reduce the effectiveness of vaccines and increase pressure on countries to vaccinate their populations quickly and outperform the globally distributed variants.

In clinical trials, the AstraZeneca-Oxford vaccine protected all participants from serious illness or death.

The Oxford scientists behind the vaccine took weekly swabs from the nose and throat of participants who had taken part in their clinical trial in the UK. To determine the effectiveness of the vaccine against the new variant, they sequenced the virus particles from several hundred swabs between October 1 and January 14. At that time it was known that the new variant was available in Great Britain.

The vaccine had 84 percent effectiveness against other lines of the virus, compared with 74.6 percent against the new variant, although the small sample sizes produced a wide range of estimates.

Andrew Pollard, the lead investigator of the vaccine study at Oxford, said in a statement that data from the study, published Friday, “indicate that the vaccine protects not only against the original pandemic virus, but also against the novel variant B.1.1. 7 that caused the rise in disease across the UK from late 2020 “

The researchers also looked at blood samples from clinical trial participants who had been vaccinated and found that the variant may be better able to evade the antibodies produced by the vaccine.

The variant, first discovered in Great Britain, has since been reported in more than 70 other countries. Public Health England has estimated that the infection rate of the variant is 25 to 40 percent higher than that of other forms of the coronavirus.

Preliminary data from laboratory tests of the Pfizer and Moderna vaccines suggest that they offer good protection against variant B.1.1.7. Novavax, which was sequencing test samples from its participants in clinical trials in the UK while the variant was widespread there, found that its vaccine against variant B.1.1.7 was highly effective.

Covid19 vaccinations>

Answers to your vaccine questions

Am I eligible for the Covid vaccine in my state?

Currently more than 150 million people – almost half of the population – can be vaccinated. But each state makes the final decision on who goes first. The country’s 21 million healthcare workers and three million long-term care residents were the first to qualify. In mid-January, federal officials asked all states to open eligibility to anyone over 65 and adults of any age with medical conditions that are at high risk of becoming seriously ill or dying of Covid-19. Adults in the general population are at the end of the line. If federal and state health authorities can remove bottlenecks in the distribution of vaccines, everyone over the age of 16 is eligible as early as spring or early summer. The vaccine has not been approved in children, although studies are ongoing. It can take months before a vaccine is available to anyone under the age of 16. For the latest information on vaccination guidelines in your area, see your state health website

Is the Vaccine Free?

You shouldn’t have to pay anything out of pocket to get the vaccine, despite being asked for insurance information. If you don’t have insurance, you should still get the vaccine for free. Congress passed law this spring banning insurers from applying cost-sharing such as a co-payment or deductible. It consisted of additional safeguards prohibiting pharmacies, doctors, and hospitals from charging patients, including uninsured patients. Even so, health experts fear that patients will end up in loopholes that make them prone to surprise bills. This may be the case for people who are charged a doctor’s visit fee with their vaccine, or for Americans who have certain types of health insurance that are not covered by the new regulations. When you get your vaccine from a doctor’s office or emergency clinic, talk to them about possible hidden costs. To make sure you don’t get a surprise invoice, it is best to get your vaccine from a Department of Health vaccination center or local pharmacy as soon as the shots become more widely available.

Can I choose which vaccine to get?How long does the vaccine last? Do I need another next year?

That is to be determined. It is possible that Covid-19 vaccinations will become an annual event just like the flu vaccination. Or the vaccine may last longer than a year. We’ll have to wait and see how durable the protection from the vaccines is. To determine this, researchers will track down vaccinated people to look for “breakthrough cases” – those people who get Covid-19 despite being vaccinated. This is a sign of a weakening of protection and gives researchers an indication of how long the vaccine will last. They will also monitor the levels of antibodies and T cells in the blood of people who have been vaccinated to see if and when a booster shot might be needed. It is conceivable that people might need boosters every few months, once a year, or just every few years. It’s just a matter of waiting for the data.

Does my employer need vaccinations?Where can I find out more?

The paper, released on Friday, did not address the protective power of the AstraZeneca vaccine against another fast-spreading variant of coronavirus known as B.1.351, which was first identified in South Africa. Researchers are running similar laboratory tests to measure the effect of this variant on the effectiveness of the vaccine.

AstraZeneca’s vaccine has been approved in nearly 50 countries around the world, but not in the United States, where the Food and Drug Administration is waiting for data from a clinical trial that included more than 30,000 participants, mostly Americans. The results of that study could be available this month, and AstraZeneca is expected to have enough safety data to seek emergency clearance from the FDA by the first week of March.

In the United States, variant B.1.1.7 has been identified in 33 states, but the full extent of its prevalence is unknown due to the lack of a national surveillance program. Federal health officials have warned that it could become the dominant form of the virus in the United States by March.

Categories
Health

Hospitals Are Nonetheless Going through Shortages of Masks and Different Protecting Gear

Hospitals Are Still Facing Shortages of Masks and Other Protective Gear

The incoming administration, he said, is exploring ways to take over the distribution of testing supplies and medical equipment. They are also trying to create financial incentives and “buy” American guidelines to bolster the handful of domestic companies that make PPE, he said. Mr Biden would not hesitate to adopt the Defense Production Act, said Dr. Bright, although he did not provide details on how it would be applied.

Industry executives say the only way to guarantee the United States a reliable supply of quality masks and other medical equipment is to recognize the sector as essential to national security, similar to the Pentagon’s approach to companies producing fighter jet components and military personnel manufacture to ensure uniforms remain viable in peacetime.

This could mean that domestic businesses receive loans and subsidies, that state and national inventory must acquire American-made medical devices, and that hospital chains may have to source some of their supplies from domestic manufacturers.

“Masks are not a huge expense,” said Mr. Bowen. “The whole damn market is less than $ 150 million.”

Dan DeLay, who oversees procurement at CommonSpirit Health, the country’s second largest nonprofit hospital chain, said the pandemic opened his eyes to the importance of home care. But it can be difficult to convince hospital managers to buy American-made protective equipment, which can cost 40 percent more than goods made overseas. “If we are serious about domestic manufacturing, we need to make serious investments that will be sustained in the long run if this happens again,” he said.

Currently, the legions of exhausted healthcare workers are focused on managing the current crisis. Mary Turner, president of the Minnesota Nurses Association, said the months of bottlenecks left many members unnoticed and angry. Ms. Turner, who is also an intensive care nurse at North Memorial Medical Center in Robbinsdale, Minnesota, recalled the days leading up to the pandemic when nurses were given an N95 mask for each patient. Nowadays she hears a lot about nurses being forced to use the masks up to ten times “or until they fall off their faces,” she said.

Despite her optimism that a Biden government will be different, it is tired of the political leaders who mark medical workers as frontline warriors but do little to protect them, she said.

“The total disregard for our security was incomprehensible,” she said. “They call us heroes, but we are not treated like soldiers in war because if we were, the federal government would make sure we have everything we need.”

Categories
Health

Moderna Vaccine Is Extremely Protecting and Prevents Extreme Covid, Knowledge Present

Moderna Vaccine Is Highly Protective and Prevents Severe Covid, Data Show

WASHINGTON – Newly released data confirmed on Tuesday that Moderna’s coronavirus vaccine offers high levels of protection and sets the stage for this week’s emergency approval from federal regulators and beginning its spread across the country.

The Food and Drug Administration intends to approve use of the vaccine on Friday, said people familiar with the agency’s plans. The decision would give millions of Americans access to a second coronavirus vaccine as early as Monday.

The FDA review confirms Moderna’s earlier assessment that the vaccine had an efficacy rate of 94.1 percent in a study of 30,000 people. Side effects, including fever, headache, and fatigue, were uncomfortable but not dangerous, the agency found.

The success of Moderna’s vaccine has become all the more important to fighting the pandemic as other vaccine efforts have stalled. The hopeful news comes at a time with a record number of coronavirus cases overwhelming hospitals and an ever-increasing death toll that hit a bleak milestone of 300,000 on Monday.

The data release is the first step in a public review process that includes a one-day meeting on Thursday by an independent panel of experts. You will hear from Moderna, FDA scientists, and the public before they vote on whether to recommend approval. The panel is expected to vote yes and the FDA generally follows the experts’ recommendations.

Distribution of about six million doses could then begin next week, significantly adding to the millions of doses already developed by Pfizer and BioNTech, the companies that only released the first emergency coronavirus vaccine last Friday . Healthcare workers received the first shots of the Pfizer BioNTech vaccine Monday with an efficacy rate of 95 percent.

The introduction of vaccines has been eagerly anticipated and is one of the most ambitious vaccination campaigns ever carried out in the United States.

Last summer, the federal government signed contracts with Moderna and Pfizer to dispense a total of 200 million cans in the first quarter of 2021. Since both vaccines require two doses, these contracts guaranteed enough doses for 100 million people.

Last week the government announced that it had bought an additional 100 million doses of Moderna for the second quarter, bringing the number of Americans who can be vaccinated to 150 million. That leaves the question of how and when the 180 million or so other Americans will be covered.

Both vaccines are made available to the public free of charge.

Moderna’s vaccine has become a symbol of government scientists’ successes during the pandemic. After China released the genetic sequence of the new virus in early January, scientists from Moderna and the National Institutes of Health were able to focus on designing a vaccine in just two days. Unlike Pfizer, Moderna has a close relationship with Operation Warp Speed, the federal program that seeks to get a vaccine to market quickly. Nearly $ 2.5 billion federal funding helped Moderna buy raw materials, expand its factory, and increase its workforce by 50 percent.

Moderna’s success contrasts with two other high profile projects the US had hoped would increase vaccine supply: one from pharmaceutical companies Sanofi from France and GlaxoSmithKline from the UK and one from Anglo-Swedish drug maker AstraZeneca and the Oxford University.

AstraZeneca and Oxford used two different doses in clinical trials in the UK and Brazil. The effectiveness was 62 percent at one level and 90 percent at the other. These jumbled results have made it unclear when AstraZeneca will have enough data to obtain an emergency clearance.

Meanwhile, Sanofi and GlaxoSmithKline received disappointing results with their vaccine in early clinical trials. While it produced a promising immune response in volunteers under the age of 50, it did not do so in older people. The companies are now planning a series of new studies with a different version of the vaccine. Due to the delay, they are unlikely to provide vaccines before the end of 2021.

Moderna’s vaccine worked equally well in white volunteers and in color communities. There was also no significant difference between protecting men and women or between healthy volunteers and those at risk for severe Covid-19 who developed conditions such as obesity and diabetes. For people aged 65 and over, the study found an estimated effectiveness of 86.4 percent, which is below the overall estimate of 94.1 percent. However, the apparent difference was not statistically significant.

So far, FDA reviews have shown two possible differences between vaccines, but the results may reflect a lack of data more than real differences. The Pfizer BioNTech study showed that the vaccine began protecting against the coronavirus within about 10 days of the first dose. The experiment with the vaccine from Moderna, however, did not show such a noticeable effect after the first dose.

However, in the early days of the Moderna study, there were fewer cases of Covid-19 among study participants, making it more difficult to measure the differences between the vaccinated group and the placebo group. In either case, health officials have said that for both vaccines, two doses are essential for complete protection.

Updated

Dec. 15, 2020 at 9:31 am ET

A second difference concerns the ability to prevent serious diseases. Moderna presented more evidence that its vaccine can, according to the review. In his study, 30 volunteers developed severe cases of Covid. All of them belonged to the placebo group, with no cases among the vaccinated people.

In the Pfizer BioNTech study, the results were less convincing. There were 10 severe cases in the placebo group and one in the vaccinated group. These numbers are too few to assess the vaccine’s ability to prevent serious diseases.

“The data available for these results did not allow firm conclusions,” said the FDA.

The documents released on Tuesday made it clear that side effects were particularly common after the second dose, but usually lasted only one day. Experts say people may need to take a day off after the shot.

During the Moderna trial, researchers also kept an eye out for volunteers who developed new disorders. In a multi-month study of 30,000 volunteers, it is normal for some to have conditions unrelated to the vaccine, health experts say. Comparing the rates between people receiving the vaccine and placebo, as well as general background rates, can help identify serious concerns and eliminate coincidences.

During the Moderna study, three vaccinated participants developed a form of temporary facial paralysis called Bell’s palsy, while one participant on the placebo experienced the same. Bell’s palsy, which can last weeks or longer, can be triggered by viral infections and other causes. Around 40,000 people develop the disease in the United States each year. Years of intensive research have found no evidence that any vaccine routinely recommended in the US causes Bell’s palsy.

In the review released Tuesday, the FDA said, “There is insufficient information currently available to establish a causal relationship with the vaccine.”

The Pfizer BioNTech study identified four cases in the vaccine group, including one in a person with a history of the disorder and none in the placebo group.

Dr. Peter Marks, the FDA’s lead vaccine regulator, said in an interview with JAMA Monday that the cases of Bell’s palsy in the study were most likely not caused by the vaccine and that the apparent difference between the two groups of volunteers was only one reason Random question.

“Our working hypothesis is just that this is an imbalance in the background rates, as we’ve seen in other studies,” he said.

In its analysis of the Moderna vaccine released Tuesday, the FDA said it plans to recommend prosecuting Bell palsy cases when the vaccines are rolled out.

“We’re going to ask about this just to wrap up that question,” said Dr. Marks on Monday.

The FDA’s analysis did not reveal any serious allergic reactions to the Moderna vaccine. The same was true for the Pfizer-BioNTech clinical trial, but when vaccinations began in the UK outside of that study, two people with a history of serious allergies had a severe and potentially life-threatening reaction called anaphylaxis.

UK health officials have said people with a history of anaphylaxis should avoid the Pfizer BioNTech vaccine.

In the United States, the Centers for Disease Control and Prevention has stated that people with serious allergies can be safely vaccinated, with close monitoring for 30 minutes after receiving the shot.

Moderna and Pfizer-BioNTech vaccines are similar in their ingredients, but not identical. Therefore, it is not clear whether an allergic reaction to one vaccine would occur with the other. Both are made up of genetic material called mRNA that is enclosed in a bladder made of a mixture of fats. The two companies use different fats.

Moderna has applied for approval to vaccinate people aged 18 and over, as in its study. The Pfizer BioNTech vaccine was approved for people aged 16 and over because the study included a number of younger volunteers. Both companies are conducting experiments with children aged 12 and over and plan to also study younger children.

Sharon LaFraniere contributed to the coverage.

[Like the Science Times page on Facebook. | Sign up for the Science Times newsletter.]